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Erythrocyte alloimmunization occurs when an individual 
produces antibodies to antigens on the donor's red blood cell, 
which the immune system identifies as a foreign element to the 
organism. It represents one of the greatest risks faced by patients 
undergoing transfusion therapy, reducing the possibility of 
finding compatible red blood cells in future transfusions. The 
immune system of the human being has the ability to recognize 
what is proper to its genome from what is not proper, being able 
to stimulate an immune reaction against foreign substances. 
Upon contact with different antigens present in the donor red 
blood cell, the recipient of the blood may trigger an immune 
response by generating antibodies against nonself antigens due to 
sensitization, such as post-pregnancy or primary transfusion, 
which may trigger lysis of transfused red blood cells. Exposure to 
large numbers of nonself antigens may lead to the formation of 
alloantibodies causing intra- or extravascular haemolytic 
transfusion reaction. Polytransfused patients are more likely to 
develop alloantibodies, approximately 1% for each transfused 
unit. This percentage may be higher in sickle cell patients (36%), 
thalassemia patients (10%) and people with myelo and 
lymphoproliferative diseases (9%). 
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Introduction 
 
The use of blood to return to homeostasis is a technique used by humans for 
centuries. The first difficulty in transfusion practice occurred in 1492, when 
Italian Pope Innocent VIII received blood transfusions from three young men in 
an attempt to save the life of the pontiff who faced severe kidney problems. The 
practice was unsuccessful, with the pope and the three donors dying shortly after 
the procedure. Several attempts were unsuccessful, such as the transfusion of 
blood from other species to man [1]. 
In 1667, French physician Jean Baptiste Denis transfused animal blood into 
humans, apparently without causing them any problems. However, on transfusing 
the patient for the second time, the patient had a Hemolytic Transfusion 
Reaction (RTH), and died sometime later. At that time, due to the great 
controversy caused, the Faculty of Medicine of Paris, together with the French 
Parliament and the Italian Pope Innocent XI prevented the practice of blood 
transfusion. The first major success of blood transfusion was performed by the 
English obstetrician and physiologist James Blundell in 1818. He transfused his 
postpartum hemorrhage patient, noting that the transfusion could only be 
performed between individuals of the same species [1]. 
The discovery of the ABO system in 1900 by Austrian physician and scientist 
Karl Landsteiner was a major achievement for transfusion therapy. He performed 
various procedures by mixing plasma and red blood cells from different people, 
noting that in some cases there was formation of cell clumps (agglutination) and 
in others not. This practice contributed to the determination of A, B and O 
blood groups. AB blood group was only discovered two years later by Alfredo 
Castello and Adriano Sturli [2,3]. 
After 40 years of the discovery of the ABO system, Landsteiner and 
Alexander Wiener announced another important system for the transfusion 
procedure: the Rh system. This system allowed the identification of blood 
according to the presence or absence of antigen D, being classified as Rh positive 
(presence of antigen D) and Rh negative (absence of antigen D). After this 
period, immunohematology was able to complete the understanding of the 
incompatibility between the different bloods that caused adverse events resulting 
from transfusions [4,5]. 
 
 
Red blood cell surface 
 
Red blood cells are non-nucleus cells that carry oxygen (O2) to all body 
tissues and remove carbon dioxide (CO2) from the tissues to be eliminated by the 
lungs. It contains within it the hemoglobin protein that carries these gases. 
Erythrocytes have an average life of 120 days. As these cells become old and 
defective, the spleen sequester them and remove them from the circulation and 
the bone marrow releases new cells into the circulation [6]. 
Red blood cells are formed by a semipermeable lipid bilayer supported by a 
protein cytoskeleton. Its membrane is composed of carbohydrates linked to 
proteins (glycoproteins) or lipids (glycolipids), asymmetrically organized, which 
are present in the cellular glycocalyx. The biochemical composition of the red 
blood cell surface is approximately 8% carbohydrate, 40% lipid and most of it 
52% protein [7,8]. In addition, the red cell membrane is characterized by the 
presence or absence of blood group antigens which are macromolecular 
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arrangements composed of carbohydrates or proteins. The diversity of genes 
involved in protein production leads to the formation of various erythrocyte 
antigens which is the major factor responsible for the formation of irregular 
antibodies in the plasma of alloimmunized individuals [2,9]. 
Since the discovery of the ABO System, studies have detected that there are 
other antigens present on the surface of red blood cells that could cause reactions 
to the transfused patient. 363 erythrocyte antigens are already known, of which 
322 are grouped in 38 different systems and the rest are in high or low frequency 
collections or series [10]. 
 
 
Risks of blood transfusion 
 
When properly evaluated and prescribed, transfusion therapy can offer 
benefits, improving quality and saving the lives of patients with severe bleeding 
[4]. Currently, transfusion medicine is one of the five most performed practices in 
the world, with 10% of hospitalized patients receiving blood transfusion 
prescriptions [11]. Chronic transfusions expose the individual to various risks 
from microorganisms, iron overload and alloimmunization [12]. 
According to a report published by the Risk Monitoring Management of the 
National Health Surveillance Agency (ANVISA), 10.547 transfusion reactions 
were reported in Brazil in the period 2007-2015. The estimate used by ANVISA 
was three reactions per 1000 transfusions, however, in its new report they 
reported that this number may be around five notifications per 1000 transfusions 
performed [13]. 
The transfusion procedure is capable of causing variable adverse reactions, 
which may be the reason for the increased morbidity and / or mortality of this 
practice. These reactions may be of immediate or late immunological origin, 
which may lead to mild to acute responses to the patient that may be prevented. 
Severe complications, which pose a fatal risk to the patient, have a lower 
incidence, while mild adverse events are common in transfusion practice, 
especially in patients on chronic transfusion regimens [8, 14, 15]. 
Among the most common causes of transfusion reactions are hemolytic 
reaction and TRALI (acute transfusion-associated lung injury). The hemolytic 
reaction occurs by the previous formation of antibodies that recognize the 
corresponding erythrocyte antigens, bind to it and cause intravascular or 
extravascular hemolysis. In TRALI there is an acute reaction with symptoms of 
respiratory distress and severe hypoxemia at the time of transfusion or up to 6 
hours after transfusion [8]. 
 
 
Erythrocyte alloimmunization 
 
The production of specific antibodies in erythrocyte alloimmunization occurs 
soon after the entry of blood containing nonself antigens present in the donor red 
blood cell. The number of transfusions received, antigenic differences, receptor 
immune response, and antigen immunogenicity are some factors that induce a 
higher rate of alloimmunization [2,8]. 
When the individual is exposed to red blood cells with different erythrocyte 
antigens through blood transfusion or pregnancy, the immune system recognizes 
transfused red blood cells as a foreign body and a specific response occurs to 
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eliminate it. When this foreign body is encountered by the immune system, B 
cells recognize, activate and secrete relevant antibodies. However, the cellular 
process involving humoral alloimmunization is quite complicated, involving 
several cell types (macrophages, dendritic cells and T lymphocytes) at different 
stages of maturation and activation [16]. 
Following this recognition, B cells produce antibodies of the IgM class as a 
primary response. Detection of these antibodies may be revealed by 
immunohematological tests within weeks to months, depending on the 
immunological response of each patient. When exposed to the same antigen a 
second time, the patient will manifest a secondary response with the production 
of IgG class immunoglobulins, which response is much faster, ranging from 48-72 
hours after the second transfusion, stimulated by memory cells (B lymphocytes) 
developed after the first transfusion [17]. 
Antibodies can be classified according to antigenic stimulus. Regular 
antibodies are those that are naturally occurring, found in individuals who have 
not at any time been exposed to antigens by transfusion, pregnancy or vaccine. 
Most of these antibodies belong to the IgM class, react better at room 
temperatures (22-24⁰C) or below, do not cross the placental barrier, may activate 
the complement system, and when activated at 37 ⁰C may cause hemolysis. 
Examples of such antibodies are those present in the ABO, Hh, li, Lewis, MN 
and P system [18]. 
Unexpectedly occurring antibodies are classified as irregular. They are 
produced as a reaction of the immune system against a nonself antigen, due to 
previous sensitization caused by the contact of erythrocyte antigens in cases of 
pregnancy or blood transfusion [3]. Most are IgG class immunoglobulins, react 
better at 37 ⁰C, are able to cross the placental barrier and can cause severe 
hemolytic reactions [18]. 
When a patient is alloimmunized, matching red blood cell pockets will be 
more difficult, requiring the location of a pouch that does not contain the antigen 
for which the patient developed the antibody on the surface of the red cell. In 
addition, the presence of alloantibodies significantly increases the risk of 
hemolytic transfusion reaction [8, 19]. 
 
 
Main erythrocyte antigens 
 
In recent years, the main objective in the practice of transfusion therapy has 
been to reduce the risk of alloimmunization in patients, especially those who need 
frequent transfusions. There are currently cataloged in the International Society 
of Blood Transfusion (ISBT) 363 erythrocyte antigens, 322 of which are classified 
into 38 different systems and 38 antigens contained in low and high frequency 
collections or series. Among these 36 different systems, we highlight the ABO, 
Rh, Kell, Duffy, Kidd, Diego, Lewis and MNS systems [10, 18, 20]. 
 
ABO system 
 
ABH antigens are formed by complex carbohydrate molecules where there is 
the interaction of A, B and H genes. The H gene is responsible for the formation 
of H antigen which is a precursor structure of the antigens of the ABO system in 
red blood cells. These genes encode the production of specific glycosyltransferases, 
which are catalyst enzymes that have the function of uniting different 
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carbohydrate structures, which add immunodominant sugars for the expression of 
an inherited blood type. About 99.99% of individuals inherit the H gene from 
their parents (HH or Hh genotype). When a person has the hh genotype, he does 
not express the H gene, and this blood type is classified as Bombay or false O [8, 
21]. 
Blood group O is a recessive phenotype, it has the precursor H gene that 
expresses only α-2-L-fucosyltransferase that will add in its terminal position the 
sugar fucose in its structure. Since group O does not have a functional enzyme, 
this individual will only express on its membrane the H antigen [2]. 
Blood type A formation is determined by the expression of A gene which will 
encode α-3-N-acetylgalactosaminyltransferase glycosyltransferase production 
which will have in the terminal region the immunodominant sugar N-acetyl-D-
galactosamine linked to the H antigen [8]. 
Blood type B formation is determined by the expression of B gene which will 
encode α-3-D-galactosyltransferase glycosyltransferase production with the 
consequent binding to the immunodominant sugar D-galactose, which sugar is 
responsible for the specificity of blood B group [8]. 
In the ABO system we find antibodies that are called natural or regular. They 
are formed from passive stimuli, such as exposure to environmental antigens, 
food, or mainly gut bacteria, which contain sugars in their cell membranes that 
are similar to the immunodominant sugars exposed in the red blood cell 
membrane [2]. 
 
Rh system 
 
After the ABO system, the Rh system is considered the most important in 
terms of transfusion. They present immunogenic antigens, that is, they have a 
greater capacity to stimulate the production of antibodies. Unlike the ABO 
system that has natural antibodies (anti-A and anti-B), the Rh system does not 
produce it and on exposure to non-self antigens will produce irregular antibodies. 
The lipoproteins of the Rh system are unique to the red blood cells and cross the 
erythrocyte membrane twelve times, forming a structure called loops, which have 
a structural and gas transport function [2, 9]. Within the Rh system, 55 different 
antigens are cataloged, and only D antigen screening in patients receiving blood 
transfusion is mandatory. However, this system has 54 different antigens that can 
cause alloimmunization and consequently hemolytic reactions [10, 22]. 
The Rh system is controlled by the RHD and RHCE genes. The RHD gene 
encodes the RhD protein, and Rh positive (D antigen) individuals have this gene 
and Rh negative (D antigen) individuals do not or cannot express this gene. The 
second gene, RHCE, encodes the expression of RhCE, RhCe, RhcE and Rhce 
proteins [8]. 
Rh system antigens may form antibodies of the G immunoglobulin class, 
which may cross the placental barrier and generate extravascular hemolytic 
reactions. Rh genes are considered codominants, with each inherited gene 
expressing the corresponding antigen. After D antigen, c antigen is the most 
immunogenic, followed by E antigen, C antigen and then e antigen [8, 9, 23]. 
More in the Rh system, CW antigen is considered a low frequency antigen, 
found in only 2% of the white population and is very rare in the black 
population. For this reason CW antigen negative blood is readily available. 
However, when the patient produce anti-CW antibodies resulting from red blood 
cell transfusion with the positive CW antigen, the patient may have clinically 
significant transfusion reactions [8]. 
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Kell system 
 
Another important system in transfusion practice is the Kell system, which 
was the first blood group system to be discovered after the introduction of the 
Coombs test. In this system 36 high and low prevalence antigens are described 
[10]. It is an antigen that has enzymatic function and is related to an endothelin 
converting enzyme, which is a potent vasoconstrictor. Kell system antibodies are 
considered strongly immunogenic, have a high incidence and are capable of 
causing severe transfusion reactions [25, 26, 27]. 
 
Duffy system 
 
The Duffy system was first reported in 1950. It has five different types of 
antigens (Fya, Fyb, Fy3, Fy5 and Fy6). Antibodies formed against this system's 
antigens belong to the IgG class, may activate the complement system and are 
clinically significant [2, 10]. Duffy glycoprotein is a receptor for proinflammatory 
chemokines and also has the function of Plasmodium vivax merozoite receptor 
(etiological agent of malaria) [24]. The incidence of this phenotype is not common 
among blacks, especially from Africa, which would explain blacks' resistance to 
malaria [8]. 
 
Kidd system 
 
The Kidd system, described between 1951 and 1953. There are cataloged in 
this system three different antigens (Jka, Jkb and Jk3) and its structure is an 
integral protein that has urea transport function. It has moderate 
immunogenicity, but is involved in severe hemolytic reactions [2]. Antigens of this 
system are of high prevalence, found in most of the population [8]. 
 
Diego system 
 
The Diego system was described in 1955. There are 22 different cataloged 
antigens in this system that have the biological function of anion transport 
(HCO3- and Cl-) and are markers of old red blood cells that must be removed 
from the bloodstream. This system can induce the formation of IgM and IgG 
class antibodies. They are low prevalence antibodies, usually associated with 
Newborn Hemolytic Disease [2, 10]. 
 
Lewis system 
 
The Lewis system was discovered in 1948 and there are six antigens (Lea, Leb, 
Leab, LebH, ALeb and BLeb) cataloged. Generally the antibodies formed are 
naturally occurring and belong to the IgM class. They rarely cause hemolytic 
reactions; however, reactivity at 37 ⁰C may activate the complement system and 
trigger severe hemolytic conditions [2]. 
 
MNS system 
 
Landsteiner and Levine discovered the MNS system shortly after the discovery 
of the ABO system. Currently 49 antigens have been described in this system, 
most of them naturally occurring and belonging to the IgM class. Anti-M and 
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anti-N antibodies are not clinically relevant, but anti-S and anti-s antibodies can 
cause severe reactions and are reactive at 37 ⁰C [10, 18]. 
 
 
Complications due to alloimmunization 
 
The most serious complication related to transfusion is the occurrence of 
Hemolytic Immune Transfusion Reaction (RTIH). This RTIH occurs when 
transfused blood is hemolysed, caused by the pre-existence of antibodies in the 
blood plasma, which may be caused by regular ABO system antibodies or by 
irregular antibodies due to alloimmunization due to previous exposure to other 
blood antigens [7].  
The severity of hemolytic transfusion reaction signs and symptoms is directly 
related to the speed and amount of incompatible blood transfused. A small 
amount of transfused blood (10 ml) can cause symptoms such as: feeling of 
impending death, pain at the infusion site, back, flanks and abdomen. In 
addition, the patient may show signs of hypotension, hemoglobinuria, 
hemoglobinemia, and shock [8].  
Binding of immunoglobulin to erythrocyte antigen may activate the 
complement system by the classical pathway and cause hemolysis. ABO 
incompatibility corresponds to the most severe hemolytic reaction, as anti-A and 
anti-B antibodies are present in large quantities in blood plasma. Intravascular 
hemolysis occurs by activation of the complement system and resulting in cell 
lysis [7, 28]. 
The antigen-antibody complex may cause extravascular hemolysis. This type 
of reaction occurs by sensitization of red blood cells by IgG class antibodies or by 
the activation of the complement system. Red blood cells bound to antibodies or 
expressing complement system proteins are phagocyted by monocytes and taken 
to the liver or spleen, where they will be destroyed in a matter of minutes, such 
as antibodies directed to the Kidd and Duffy system. This recognition can also 
occur when the monocyte recognizes and binds to the antibody without 
complement system activation [8, 28].  
Another type of reaction resulting from alloimmunization is Late Haemolytic 
Immune Transfusion Reaction (RTIHT) which causes extravascular hemolysis 
and usually occurs 24 hours to two weeks after blood transfusion and is directed 
primarily against the Rh, Kidd, Duffy and Kell antigens [2, 7]. 
 
 
Strategies for the prevention of alloimmunization 
 
Erythrocyte phenotyping is based on identifying which antigens are exposed 
on the surface of red blood cells. Currently, Brazilian legislation recommends 
testing prior to the act of blood transfusion, which includes ABO phenotyping, 
RhD phenotyping, Irregular Antibody Research and Compatibility test, observing 
whether or not agglutination reaction [22, 29]. 
However, patients with chronic transfusions are more likely to develop 
alloantibodies because they are exposed to a wide variety of different antigens 
with each transfusion. Phenotyping patients and blood bags against other more 
prevalent antigens is a way to significantly reduce alloimmunization [30]. 
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Several studies point out that most antibodies produced by alloimmunization 
belong to the Rh and Kell systems, the most prominent being E, e, C, c, Cw and 
Kell [27, 30]. Therefore, research on these antigens can be very helpful in 
reducing the risk of alloimmunization [26]. According to the need for 
Hemotherapy services, the Brazilian Ministry of Health recommends phenotyping 
of Rh (D, C, c, E, e) and Kell (K1) erythrocyte antigens in blood samples from 
blood donors. In addition, for patients who may undergo chronic transfusion 
regimens, phenotyping for the erythrocyte antigens of the Rh (E, e, C, c), Kell 
(K), Duffy (Fya, Fyb), Kidd (Jka, Jkb) systems and MNS (S, s) can be a great 
help for the prevention of alloimmunization [22].  
 
 
Conclusions 
 
The performance of blood transfusion was a landmark of great relevance for 
medicine. Blood is an important therapeutic tool that continues to contribute 
more and more to the survival and quality of life of people who need frequent 
transfusions, either by surgical procedures requiring replacement of lost blood, or 
by degenerative and chronic diseases. 
However, it is necessary that blood transfusion be seen as a complex 
procedure, as well as a transplant, which may trigger greater risks than benefits 
to the patient. Knowing the diversity of antigens that may be present in the 
donor's red blood cell and understanding how the recipient patient's immune 
system may respond to this procedure is crucial to understanding the great 
responsibility of subjecting a patient to blood transfusion. 
Laboratory tests, identifying possible problems that may occur at the time of 
transfusion, are of great importance for the success of the procedure. However, for 
patients with chronic transfusion regimens, it would be important to adopt 
conducts for identifying other blood systems besides the ABO / RhD systems, 
with extended phenotyping of the MNS (S, s), Duffy (Fya, Fyb), Kidd (Jka, Jkb) 
systems and mainly Kell (K) and Rh (E, e, C, c) system antigens. 
The correct assessment and prescription of blood transfusion by the attending 
physician in conjunction with preventive and safe measures adopted by 
transfusion agencies, matching the ABO, Rh (D, E, e, C, c) and Kell systems, 
may offer a lower chance of erythrocyte alloimmunization may occur in 
polytransfused patients. 
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